Dr Alap Christy, VP & Scientific Business Head of Clinical Chemistry at Metropolis Healthcare, India, provides insights on how the HCV Ag-Ab dual assay not only shortens the current lengthy diagnostic window period from infection to anti-HCV seroconversion, it also simplifies the diagnostic algorithm. He also shared a real-world case where HCV Ag-Ab dual assay played a pivotal role in a transplant surgeon’s clinical decision-making, further demonstrating its clinical utility in enhancing patient care.